Author | Pons, Andréa Henriques | |
Author | Oliveira, Gabriel Melo de | |
Access date | 2019-01-08T11:23:08Z | |
Available date | 2019-01-08T11:23:08Z | |
Document date | 2009 | |
Citation | PONS, Andrea Henriques; OLIVEIRA, Gabriel Melo de. Is the Fas/Fas-L Pathway a Promising Target for Treating Inflammatory Heart Disease?. J Cardiovasc PharmacolTM, v.53, p.94-99, 2009. | pt_BR |
ISSN | 0160-2446 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/30908 | |
Language | eng | pt_BR |
Publisher | Lippincott, Williams & Wilkins | pt_BR |
Rights | restricted access | pt_BR |
Subject in Portuguese | Inflamação | pt_BR |
Subject in Portuguese | Miocardite | pt_BR |
Subject in Portuguese | Tratamento | pt_BR |
Title | Is the Fas/Fas-L Pathway a Promising Target for Treating Inflammatory Heart Disease? | pt_BR |
Type | Article | pt_BR |
Abstract | The elucidation of the intricate molecular network of
costimulus and regulatory pathways of the immune system led to
the design of molecular therapies that specifically inactivate some
cellular responses and ameliorate some autoimmune and inflammatory
diseases. This innovative concept opens a new class of therapies,
and one of the central components that could be targeted in future
molecular therapies is the Fas-based pathway. Both soluble and
membrane-bound Fas and Fas-L molecules exert a wide range of
proinflammatory functions through the secretion of cytokines and
chemokines, cellular chemotaxis, transcriptional regulation, cellular
death, and others. Accordingly, many chronic inflammatory diseases,
including myocarditis, are attenuated in mice lacking either molecule.
Although it is tempting to speculate that the Fas/Fas-L pathway could
be targeted for in vivo myocarditis therapy, the plurality of Fas/Fas-L
functions can be an obstacle, leading to important side effects. In this
review, we suggest that the injection of nonagonistic antibodies raised
against the Fas molecule or the inactivation of downstream Fas-1,4,5-
inositol triphosphate cascade are possible targets for myocarditis
treatment. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ. Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ. Brasil. | pt_BR |
Subject | Fas/Fas-L | pt_BR |
Subject | inflammation | pt_BR |
Subject | myocarditis | pt_BR |
Subject | treatment/therapy | pt_BR |
e-ISSN | 1533-4023 | |
Embargo date | 2030-01-01 | |